In the BioHarmony Drug Report Database

"Preview" Icon

Dactinomycin

Cosmegen, Cubicin (dactinomycin) is a protein pharmaceutical. Dactinomycin was first approved as Cosmegen on 1982-01-01. It is used to treat choriocarcinoma, ewing sarcoma, gestational trophoblastic disease, kaposi sarcoma, and melanoma amongst others in the USA. It has been approved in Europe to treat bacteremia, bacterial endocarditis, bacterial skin diseases, gram-positive bacterial infections, and soft tissue infections.

 

Trade Name

 

Cubicin
 

Common Name

 

dactinomycin
 

ChEMBL ID

 

CHEMBL1554
 

Indication

 

bacteremia, bacterial endocarditis, bacterial skin diseases, choriocarcinoma, ewing sarcoma, gestational trophoblastic disease, gram-positive bacterial infections, kaposi sarcoma, melanoma, neuroblastoma, retinoblastoma, rhabdomyosarcoma, soft tissue infections, soft tissue neoplasms, testicular neoplasms, uterine neoplasms, wilms tumor
 

Drug Class

 

Antibiotics (Streptomyces strains)

Image (chem structure or protein)

Dactinomycin structure rendering